LPCN
Income statement / Annual
Last year (2023), Lipocine Inc.'s total revenue was -$2.85 M,
a decrease of 670.16% from the previous year.
In 2023, Lipocine Inc.'s net income was -$16.35 M.
See Lipocine Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
-$2.85 M
|
$500,000.00
|
$16.14 M
|
$0.00
|
$164,990.00
|
$428,031.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit |
-$2.85 M |
$500,000.00 |
$16.14 M |
$0.00 |
$164,990.00 |
$428,031.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit Ratio |
1 |
1 |
1 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
Research and Development
Expenses |
$10.18 M
|
$8.56 M
|
$7.67 M
|
$9.75 M
|
$7.47 M
|
$6.46 M
|
$11.00 M
|
$8.08 M
|
$12.58 M
|
$15.48 M
|
General & Administrative
Expenses |
$4.90 M
|
$4.06 M
|
$5.33 M
|
$8.25 M
|
$5.60 M
|
$5.29 M
|
$10.21 M
|
$10.38 M
|
$5.80 M
|
$5.00 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$4.90 M
|
$4.06 M
|
$5.33 M
|
$8.25 M
|
$5.60 M
|
$5.29 M
|
$10.21 M
|
$10.38 M
|
$5.80 M
|
$5.00 M
|
Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Operating Expenses |
$15.08 M |
$11.80 M |
$16.64 M |
$20.65 M |
$12.83 M |
$12.09 M |
$20.98 M |
$18.97 M |
$18.38 M |
$20.48 M |
Cost And Expenses |
$15.08 M |
$11.80 M |
$16.64 M |
$20.65 M |
$12.83 M |
$12.09 M |
$20.98 M |
$18.97 M |
$18.38 M |
$20.48 M |
Interest Income |
$1.37 M |
$545,480.00 |
$135,592.00 |
$310,968.00 |
$343,254.00 |
$0.00 |
$0.00 |
$0.00 |
$173,890.00 |
$108,338.00 |
Interest Expense |
$0.00 |
$27,098.00 |
$203,292.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$28,661.00
|
$9,453.00
|
$380.00
|
$3,554.00
|
$15,443.00
|
$18,595.00
|
$28,370.00
|
$31,960.00
|
$26,721.00
|
$14,620.00
|
EBITDA |
-$16.32 M
|
-$10.72 M
|
-$430,527.00
|
-$17.99 M
|
-$12.65 M
|
-$11.31 M
|
-$21.19 M
|
-$18.94 M
|
-$18.36 M
|
-$20.47 M
|
EBITDA Ratio |
5.73 |
-24.22 |
0.19 |
0 |
-78.09 |
-26.42 |
0 |
0 |
0 |
0 |
Operating Income Ratio
|
6.29
|
-24.24
|
0.19
|
0
|
-78.19
|
-26.46
|
0
|
0
|
0
|
0
|
Total Other
Income/Expenses Net |
$1.58 M
|
$1.36 M
|
-$3.78 M
|
-$2.97 M
|
-$106,854.00
|
-$333,503.00
|
$235,816.00
|
$216,078.00
|
$173,890.00
|
$108,338.00
|
Income Before Tax |
-$16.35 M |
-$10.76 M |
-$634,199.00 |
-$20.96 M |
-$13.01 M |
-$11.66 M |
-$20.98 M |
-$18.97 M |
-$18.21 M |
-$20.37 M |
Income Before Tax Ratio
|
5.74
|
-21.52
|
-0.04
|
0
|
-78.84
|
-27.24
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$755.00 |
$681.00 |
$200.00 |
$200.00 |
$200.00 |
$700.00 |
$700.00 |
$752.00 |
$200.00 |
$200.00 |
Net Income |
-$16.35 M |
-$10.76 M |
-$634,399.00 |
-$20.96 M |
-$13.01 M |
-$11.66 M |
-$20.98 M |
-$18.97 M |
-$18.21 M |
-$20.37 M |
Net Income Ratio |
5.74 |
-21.52 |
-0.04 |
0 |
-78.84 |
-27.24 |
0 |
0 |
0 |
0 |
EPS |
-3.14 |
-2.15 |
-0.19 |
-6.46 |
-8.54 |
-9.35 |
-17.79 |
-17.66 |
-18.79 |
-27.13 |
EPS Diluted |
-3.14 |
-2.05 |
-0.12 |
-6.4 |
-8.54 |
-9.28 |
-17.85 |
-17.68 |
-18.87 |
-27.2 |
Weighted Average Shares
Out |
$5.27 M
|
$4.99 M
|
$3.30 M
|
$3.25 M
|
$1.52 M
|
$1.25 M
|
$1.18 M
|
$1.07 M
|
$964,937.00
|
$748,995.00
|
Weighted Average Shares
Out Diluted |
$5.27 M
|
$5.26 M
|
$5.15 M
|
$3.28 M
|
$1.52 M
|
$1.26 M
|
$1.18 M
|
$1.07 M
|
$968,871.00
|
$750,958.00
|
Link |
|
|
|
|
|
|
|
|
|
|